Repurposing Leptin: How a “Fat Drug” Became a Model for a Leaner Industry
This article was originally published in RPM Report
Two decades ago, the “fat dissolving” protein leptin was touted as one of the biggest opportunities in biotech—based on preclinical rodent studies. The compound may finally be making it to market in a very different model: as an orphan drug sponsored by Big Pharma.
You may also be interested in...
Two decades after the “obesity gene” was the hottest story in biotech, a product from that research is finally going to reach the market. But it is for a disease that occurs in about .0001% of the US population.
Bristol-Myers and AstraZeneca’s acquisition of Amylin as part of a 50-50 collaboration brings a big new player into the fast-growing GLP-1 class, which is emerging as a key component of treatment in the large, but highly competitive Type 2 diabetes market.
Discontinuation is unrelated to prior safety suspension, say Amylin and Takeda, who acknowledge that "this is a difficult time for innovators and regulators."